Abstract:The bovine spongiform encephalopathy (BSE) epidemic, along with the related threat to human health posed by the transmission of the BSE agent to humans, has highlighted the importance of prion diseases. These fatal neurodegenerative diseases are characterised by spongiform changes in the CNS, and comprise a wide spectrum of clinicopathological entities in humans and animals, such as Creutzfeldt-Jakob disease (CJD) and its emerging new variant (vCJD) in humans, and BSE and scrapie in animals. This article reviews the geographical distribution and the temporal trends of CJD and vCJD; the major events in the pathogenesis of prion diseases; the risk factors for sporadic CJD and vCJD; and the possible strategies for treating them. Worldwide statistics indicate that sporadic CJD has a stable incidence of one case per million people per year; in contrast, the incidence of vCJD appears to have increased exponentially from its characterisation in 1994 to a peak in 2000. As of December 2005, 183 definite or probable cases of vCJD had been reported worldwide. The crucial event in the pathogenesis of prion diseases is the conversion of the normally occurring cellular prion protein (PrP(c)) into a pathogenic form, called protease-resistant PrP (PrP(res)) or scrapie PrP (PrP(sc)). Pathogenetic studies in rodent models have shown that PrP(sc) is found in the enteric nervous system and in the gut-associated lymphoid tissue following oral scrapie ingestion. The role of the lymphoreticular system in the pathogenesis of TSE seems to be related to the strains of agents and the host genotype. Therapeutic approaches to vCJD are mainly based on the inhibition or prevention of the pathological change that creates PrP(sc). Derivatives of acridine (such as mepacrine [quinacrine]) and the phenothiazine psychotropics have been proposed as possible therapies because of their activity in cellular models; however, neither class was able to affect the protease resistance of preexisting PrP fibrils. More encouragingly, in animal models of prion disease, tetracyclines were found to reduce prion infectivity by direct inactivation of PrP(sc). While these findings are promising, the suitability of these compounds for clinical use is still limited by their low efficacy once symptoms are apparent. Treatments based on the vaccination approach have also produced positive results, but further investigations are necessary to establish their clinical application.

Stochastic Modelling Approach to the Incubation Time of Prionic Diseases

The dynamics of prion spreading is governed by the interplay between the non-linearities of tissue response and replication kinetics

PrP(Sc) of Scrapie 263K Propagates Efficiently in Spleen and Muscle Tissues with Protein Misfolding Cyclic Amplification.

Expression of PrP(C) As HIS-fusion Form in a Baculovirus System and Conversion of Expressed PrP-sen to PrP-res in a Cell-Free System.

Understanding Intra-Species and Inter-Species Prion Conversion and Zoonotic Potential Using Protein Misfolding Cyclic Amplification

Oscillations in neuronal activity: a neuron-centered spatiotemporal model of the Unfolded Protein Response in prion diseases

Protein Misfolding Cyclic Amplification Cross-Species Products of Mouse-Adapted Scrapie Strain 139A and Hamster-Adapted Scrapie Strain 263K with Brain and Muscle Tissues of Opposite Animals Generate Infectious Prions

Bimodality, prion aggregates infectivity and prediction of strain phenomenon

Prions, BSE and food

Effects of a naturally occurring amino acid substitution in bovine PrP: a model for inherited prion disease in a natural host species

Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of transmissible and rapidly progressive neurodegenerative diseases including Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI) in humans, bovine spongiform encephalopathy (BSE) in cattle, scrapi

Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances

Development of a methodology for large-scale production of prions for biological and structural studies

Interactions between Cytokines and the Pathogenesis of Prion Diseases: Insights and Implications

The Structure of the Infectious Prion Protein and Its Propagation

Prions and protein-folding diseases

A mathematical model of the dynamics of prion aggregates with chaperone-mediated fragmentation

A multigroup approach to delayed prion production

Modeling of Bovine Spongiform Encephalopathy in a Two-Species Feedback Loop

Analysis of a model for the dynamics of prions II